Kreos Capital, the leading growth debt provider in Europe and Israel, led the debt financing to enhance the company’s capital resources ahead of commercial expansion
TEL AVIV, ISRAEL – September 28, 2022 – Scopio Labs, “Scopio” developer of Full-Field Cell Morphology™ imaging and AI-powered analysis platforms to support laboratory professionals in the detection and monitoring of blood-related diseases, announced today a $15M debt financing led by Kreos Capital. These additional funds follow the recent $50M Series C equity financing announced by Scopio in February 2022.
The capital resources will be used to meet growing international demand for Scopio’s haematology analysis platforms, the X100 and X100HT. Scopio is accelerating global commercial expansion to meet this increased market demand.
“We have achieved several key milestones this year, including Series C funding, strategic distribution partnerships, FDA clearance for our 100X HT (High-Throughput) platform with Full-Field Peripheral Blood SmearTM application, and the European launch of our new Full-Field Bone Marrow AspirateTM Application,” said Itai Hayut, Co-Founder and CEO of Scopio Labs. They added “This additional financing, combined with the equity investment secured earlier this year, enhances our ability to meet growing demand for our products”.
Aris Constantinides, General Partner of Kreos Capital commented, “We have been financial partners with Scopio since our original debt investment in 2020 and have witnessed first-hand the successful development of the product and achievement of consecutive milestones. We are excited to be expanding our partnership with Scopio to fund the company’s continued product development and commercial expansion”.
About Scopio Labs
Scopio Labs is transforming cell morphology analysis, offering a suite of fully digital applications and platforms that enhance clinical workflows and assists lab experts with faster, earlier, and accurate detection of diseases.
Solving the tradeoff between field-of-view and resolution, Scopio enables labs to assess and analyse cell morphology at unprecedented scale and depth. The company’s combination of high-resolution imaging and an AI-powered decision support system makes the diagnostic process more efficient across the continuum of care.
Scopio Labs’ FDA-cleared, CE-marked X100 and X100HT with the Full-Field Peripheral Blood Smear Application is in full commercial use across the U.S. and Europe. To learn more, visit: https://scopiolabs.com/.
About Kreos Capital
Kreos Capital is the leading growth debt provider in Europe and Israel, backing high-growth companies through every stage of their life-cycle. Kreos targets investments in all areas of the Technology and Healthcare sectors and, to date, has committed €4.2 billion in more than 700 portfolio company transactions, across 18 countries. With over €2.0 billion in current funds under management Kreos can invest between €2 million and €100 million per transaction in both public and private companies across all stages. www.kreoscapital.com
Source: Scopiolabs.com
Image Source: https://en.globes.co.il/
